retatrutide clinical trial parkinson Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP retatrutide parkinson clinical trial retatrutide

Some protocols describe injecting near the area of interest (for example, close to an injured tendon in animal research), based on the hypothesis of a localized effect

Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K

According to the SURPASS program, which included five studies, researchers reported that a weekly dose of tirzepatide at 15 mg significantly reduced systolic blood pressure by as much as 12.6 mm Hg [97]

CJC-1295 and Ipamorelin are prescription therapies that must be evaluated, dosed, and supervised by a licensed medical provider, and individual results vary

Semaglutide GLP-1 is also not recommended for individuals with a history of severe gastrointestinal disease or gastroparesis, as it may exacerbate these conditions